127 related articles for article (PubMed ID: 17306348)
1. An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer.
Suga S; Kato K; Ohgami T; Yamayoshi A; Adachi S; Asanoma K; Yamaguchi S; Arima T; Kinoshita K; Wake N
Gynecol Oncol; 2007 May; 105(2):341-50. PubMed ID: 17306348
[TBL] [Abstract][Full Text] [Related]
2. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
[TBL] [Abstract][Full Text] [Related]
3. A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation.
Brekman A; Singh KE; Polotskaia A; Kundu N; Bargonetti J
Breast Cancer Res; 2011 Jan; 13(1):R3. PubMed ID: 21223569
[TBL] [Abstract][Full Text] [Related]
4. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide (As2O3) inhibits expression of estrogen receptor-alpha through regulation of the mitogen-activated protein kinase (MAPK) pathway in endometrial cancer cells.
Bae-Jump VL; Zhou C; Boggess JF; Gehrig PA
Reprod Sci; 2008 Dec; 15(10):1011-7. PubMed ID: 19088370
[TBL] [Abstract][Full Text] [Related]
6. Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway.
Kundu N; Brekman A; Kim JY; Xiao G; Gao C; Bargonetti J
Oncotarget; 2017 Jul; 8(29):47916-47930. PubMed ID: 28615518
[TBL] [Abstract][Full Text] [Related]
7. Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles.
Yu H; Zou Y; Jiang L; Yin Q; He X; Chen L; Zhang Z; Gu W; Li Y
Biomaterials; 2013 Apr; 34(11):2738-47. PubMed ID: 23352573
[TBL] [Abstract][Full Text] [Related]
8. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
9. High-dose estrogen and clinical selective estrogen receptor modulators induce growth arrest, p21, and p53 in primate ovarian surface epithelial cells.
Wright JW; Stouffer RL; Rodland KD
J Clin Endocrinol Metab; 2005 Jun; 90(6):3688-95. PubMed ID: 15755852
[TBL] [Abstract][Full Text] [Related]
10. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway.
Li M; Zhang Z; Hill DL; Wang H; Zhang R
Cancer Res; 2007 Mar; 67(5):1988-96. PubMed ID: 17332326
[TBL] [Abstract][Full Text] [Related]
11. CALB1 enhances the interaction between p53 and MDM2, and inhibits the senescence of ovarian cancer cells.
Cao LQ; Wang YN; Liang M; Pan MZ
Mol Med Rep; 2019 Jun; 19(6):5097-5104. PubMed ID: 31059057
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
Gysin S; Lee SH; Dean NM; McMahon M
Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
[TBL] [Abstract][Full Text] [Related]
13. Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
Choi HJ; Chung TW; Kang SK; Lee YC; Ko JH; Kim JG; Kim CH
Glycobiology; 2006 Jul; 16(7):573-83. PubMed ID: 16574813
[TBL] [Abstract][Full Text] [Related]
14. Beta-hydroxyisovalerylshikonin has a profound anti-growth activity in human endometrial and ovarian cancer cells.
Takai N; Ueda T; Nishida M; Nasu K; Narahara H
Gynecol Oncol; 2008 Apr; 109(1):107-14. PubMed ID: 18234298
[TBL] [Abstract][Full Text] [Related]
15. The cholesterol metabolite 27-hydroxycholesterol regulates p53 activity and increases cell proliferation via MDM2 in breast cancer cells.
Raza S; Ohm JE; Dhasarathy A; Schommer J; Roche C; Hammer KD; Ghribi O
Mol Cell Biochem; 2015 Dec; 410(1-2):187-95. PubMed ID: 26350565
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis.
Jiang CC; Chen LH; Gillespie S; Wang YF; Kiejda KA; Zhang XD; Hersey P
Cancer Res; 2007 Oct; 67(20):9750-61. PubMed ID: 17942905
[TBL] [Abstract][Full Text] [Related]
17. Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest.
Giono LE; Manfredi JJ
Mol Cell Biol; 2007 Jun; 27(11):4166-78. PubMed ID: 17371838
[TBL] [Abstract][Full Text] [Related]
18. Significant anti-proliferation of human endometrial cancer cells by combined treatment with a selective COX-2 inhibitor NS398 and specific MEK inhibitor U0126.
Gao J; Niwa K; Takemura M; Sun W; Onogi K; Wu Y; Seishima M; Mori H; Tamaya T
Int J Oncol; 2005 Mar; 26(3):737-44. PubMed ID: 15703831
[TBL] [Abstract][Full Text] [Related]
19. Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition.
Ring KL; Yates MS; Schmandt R; Onstad M; Zhang Q; Celestino J; Kwan SY; Lu KH
Int J Gynecol Cancer; 2017 Jun; 27(5):854-862. PubMed ID: 28498246
[TBL] [Abstract][Full Text] [Related]
20. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
Phelps M; Darley M; Primrose JN; Blaydes JP
Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
